Cotadutide (MEDI0382) acetate is a potent dual agonist ofglucagon-like peptide-1 (GLP-1)andGCGRwithEC₅₀values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D)^[1][2][3].

EC50: 6.9 pM (GLP-1); 10.2 pM (GCGR)^[1]

Cotadutide acetate stimulates a concentration-dependent increase in cAMP accumulation in rat (INS-1 832/3) and human (EndoC-βH1) β-cell lines (EC₅₀: 226 pM and 1051 pM, respectively ), as well as rat, mouse and human hepatocytes (EC₅₀: 462 pM, 840 pM, 1447 pM, respectively)^[1].
Cotadutide (100 pM-1 μM) acetate potentiates glucose-stimulated insulin secretion in the rat (INS-1 832/3) pancreatic β‐cell line and increases glucose output in rat hepatocytes^[1].
Cotadutide (100 nM, 2 h) acetate induces mitochondrial turnover and enhances mitochondrial function in mouse primary hepatocytes^[2].

Cotadutide (10 nmol/kg, s.c., once) acetate suppresses food intake in DIO mice relative to vehicle‐ reated controls^[1].
Cotadutide (10 or 30 nmol/kg, s.c., once daily for 14-16 weeks) acetate reduces body weight in DIO mice^[1].
Cotadutide (30 nmol/kg, s.c., once a day for 6 weeks) acetate reduces hepatic fibrosis and inflammation in in ob/ob AMLN NASH mice^[2].

3788.14

Solid

C₁₆₉H₂₅₆N₄₂O₅₇

1'-{palmtoyl-Glu}; His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Lys-Ser-Glu-Tyr-Leu-Asp-Ser-Glu-Arg-Ala-Arg-Asp-Phe-Val-Ala-Trp-Leu-Glu-Ala-Gly-Gly (Amide bridge: Glu1'-Lys10)

1'-{palmtoyl-Glu}; HSQGTFTSDKSEYLDSERARDFVAWLEAGG (Amide bridge: Glu1'-Lys10)

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

DMSO : 12.5 mg/mL(3.30 mM;Need ultrasonic)

H₂O : 2 mg/mL(0.53 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: 1.25 mg/mL (0.33 mM); Suspended solution; Need ultrasonic

  此方案可获得 1.25 mg/mL (0.33 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

  Solubility: 1.25 mg/mL (0.33 mM); Suspended solution; Need ultrasonic

  此方案可获得 1.25 mg/mL (0.33 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 1.25 mg/mL (0.33 mM); Clear solution

  此方案可获得 ≥ 1.25 mg/mL (0.33 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。